Regeneron says its Covid-19 treatment reduces viral levels, improves symptoms | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Thursday
June 08, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
THURSDAY, JUNE 08, 2023
Regeneron says its Covid-19 treatment reduces viral levels, improves symptoms

Coronavirus chronicle

Reuters
30 September, 2020, 08:40 am
Last modified: 30 September, 2020, 12:57 pm

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

Regeneron says its Covid-19 treatment reduces viral levels, improves symptoms

Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack

Reuters
30 September, 2020, 08:40 am
Last modified: 30 September, 2020, 12:57 pm
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US September 17, 2020/ Reuters
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, US September 17, 2020/ Reuters

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalised Covid-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide.

"We hope these data will support an EUA" (emergency use authorization) from the US Food and Drug Administration, Regeneron Chief Scientific Officer George Yancopoulos said on a conference call.

The FDA can authorise emergency use of a drug before completing its review for a formal approval.

The treatment, REGN-COV2, is also being studied for use in hospitalised patients, and for prevention of infection in people who have been exposed to Covid-19. Regeneron declined to comment on when those trial results are expected.

"It is unclear, though possible, that the Regeneron cocktail could work in a hospital setting where the patient is already severely ill and has a high viral load," Jefferies analyst Michael Yee said in a research note.

Yancopoulos said that in order for REGN-COV2 to be used in the studied patient population - people with mild-to-moderate Covid-19 - routine diagnostic tests would be needed. Therapeutic use "is going to depend on having the right diagnostic tools available," he said.

Shares of Regeneron were up 2% at $585.40 after hours.

Trial results for the first 275 patients showed the biggest effect in patients who did not create high levels of their own antibodies against the virus. That suggests the REGN-COV2 could help patients whose own immune system is not strong enough to combat the virus, Regeneron said.

The drug is part of a class of biotech therapies known as monoclonal antibodies. Several companies are using the technology to manufacture copies of human antibodies to the new coronavirus.

Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack.

Eli Lilly & Co earlier this month released data showing that one of its monoclonal antibodies lowered patient virus levels and could reduce the need for patients to be hospitalised.

Regeneron tested two different doses of REGN-COV2 in two patient populations: those who had mounted an effective immune response on their own (seropositive), and those whose immune response was not yet adequate (seronegative).

In seronegative patients, the median time to symptom relief was 13 days for the placebo group, 8 days for the high-dose group and 6 days for the low-dose group.

Regeneron said REGN-COV2 rapidly reduced virus levels in seronegative patients. In addition, patients with higher virus levels at the start of the trial had correspondingly greater reductions in viral load with REGN-COV2, which is given by intravenous infusion.

"The data are favorable for seronegative patients," Yee said.

The US government in June awarded Regeneron a $450 million supply contract for up to 300,000 doses of the antibody cocktail.

Swiss drugmaker Roche Holding AG last month agreed to boost overall manufacturing capacity for REGN-COV2 by at least three-and-a-half times. Under the deal, Regeneron would handle US sales of the treatment and Roche would be responsible for the rest of the world.

Top News / World+Biz

Regeneron / covid-19 vaccine / Covid-19 Antibody

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    Factory owners stare at losses as power cuts bring down production
  • Photo: BSS
    President Shahabuddin urges UK entrepreneurs to invest in oil, gas sectors
  • Photo: Collected
    Eight small children injured in knife attack in French alpine town

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

Features

Apple does not need to make mixed reality seem exciting to get customers through its doors. They’re turning up in droves anyway, to buy new iPhones or to visit the Genius Bar for IT support. Photo: Bloomberg

Apple has 520 reasons its $3,499 headset will prevail

1h | Panorama
Md Shamsuddoha. Sketch: TBS

'Extreme heat waves are here to stay'

2h | Panorama
Kestopur’s residents have crafted fans for generations and provided it to Rajbari, Faridpur, Kustia, Madaripur, Dhaka and several other districts. Photo: Masum Billah

Talpakha: When novelty becomes necessity

6h | Panorama
Illustration: TBS

Why aspiration mismatch is a bigger challenge than skill mismatch

1d | Pursuit

More Videos from TBS

Breaching the Kakhovka dam – who benefits?

Breaching the Kakhovka dam – who benefits?

1h | TBS World
The cost of rechargeable fan is increasing hourly due to heating and load shedding

The cost of rechargeable fan is increasing hourly due to heating and load shedding

4h | TBS Today
Iran’s hypersonic missile stuns world

Iran’s hypersonic missile stuns world

4h | TBS World
DU students are suffering due to electricity

DU students are suffering due to electricity

1d | TBS Stories

Most Read

1
bKash denied permission to pay $4.10 lakh for Argentina football partnership
Banking

bKash denied permission to pay $4.10 lakh for Argentina football partnership

2
Photo: Noor-A-Alam/TBS
Splash

The Night Dhaka did NOT vibe with Anuv Jain

3
Photo: TBS
Energy

2nd unit of Payra power plant to shut down over coal shortage

4
Country's first floating solar power plant connected to national grid
Energy

Country's first floating solar power plant connected to national grid

5
Photo: Screengrab from a video posted by a NSU student
Energy

'Will collapse any moment': NSU teachers, students raise concern after long power outage hit country's largest private uni

6
Photo: Salahuddin Ahmed Paulash/TBS
Energy

LPG price drops by Tk13.42 per kg

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]